Doses of OAMs are required to have been stable for at least 90 days prior to screening.
Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.
Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.
You may not be if
Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune diabetes in adults.
Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening.
Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis within 6 months prior to screening.
Have hypoglycemia unawareness as judged by the investigator.
